Report Highlights

U.S. Propolis Market: Market Overview

The U.S. propolis market is structured almost entirely around the Dietary Supplement Health and Education Act of 1994 (DSHEA), which governs how propolis can be labeled, marketed, and sold to American consumers. Under DSHEA, propolis products must not claim to diagnose, cure, treat, or prevent any disease, restricting brands to structure-function claims. The market generated USD 412.6 million in 2024, with dietary supplements — primarily capsules, tinctures, and lozenges — accounting for the dominant share. The FDA's Center for Food Safety and Applied Nutrition (CFSAN) regulates propolis labeling, while the Federal Trade Commission enforces advertising standards for health claims made outside the product label.

Government agencies have not been the growth engine in this market; private sector demand driven by consumer interest in natural immunity support and antimicrobial ingredients has led expansion. However, regulatory inaction has shaped the market's ceiling. The USDA's National Organic Program (NOP) does certify organic propolis, and NOP-certified products command a 30–40% price premium, creating a meaningful quality tier. The USDA Agricultural Marketing Service published beekeeping data through its National Agricultural Statistics Service (NASS), which confirms the domestic supply shortfall. The private sector — particularly direct-to-consumer supplement brands — has absorbed this constraint by building import supply chains from Brazil, China, and New Zealand.

Policy-Driven Growth in U.S. Propolis

Three specific policy mechanisms are generating measurable demand growth for propolis in the United States. First, the Honeybee Health Coalition's activities, funded in part through USDA Agricultural Research Service (ARS) grants under the Specialty Crop Research Initiative (SCRI), have expanded awareness of hive-derived bioactives commercially. The SCRI program allocated USD 40 million to specialty crop research in its FY2023 cycle, a portion of which directly funds apiary productivity studies that validate propolis yield improvement, strengthening the domestic supply narrative and encouraging downstream investment by supplement manufacturers.

Second, the National Institutes of Health's National Center for Complementary and Integrative Health (NCCIH) funded propolis-related clinical trials totaling over USD 3.2 million between 2019 and 2024, lending scientific legitimacy that accelerates retailer adoption. Third, USDA's Organic Transition Initiative, launched in 2022 with USD 300 million in funding, incentivizes beekeepers to pursue NOP organic certification for propolis operations, increasing the supply of certified organic raw material that commands premium pricing and enables brands to access natural retail channels including Whole Foods Market's supplier requirements for organic ingredients. Each mechanism translates into expanded product lines and higher wholesale purchase volumes.

Regulatory Barriers and Compliance Costs

The most significant regulatory barrier is the FDA's Current Good Manufacturing Practice (cGMP) requirements for dietary supplements, codified under 21 CFR Part 111 and administered by the FDA's Office of Regulatory Affairs. Small and mid-sized propolis supplement manufacturers face cGMP audit and remediation costs averaging USD 150,000–USD 400,000 per facility per compliance cycle. Import entry is an additional friction point: propolis raw material imported from Brazil or China must pass FDA Import Alert screening, and shipments flagged under Import Alert 54-15 for adulterated bee products can be detained without physical examination, causing supply delays of 30 to 90 days that directly increase inventory carrying costs for domestic formulators.

A second material barrier is the Federal Trade Commission's enforcement of advertising standards under Section 5 of the FTC Act and its Health Products Compliance Guidance, updated in 2022. Propolis brands making immune support claims in digital advertising — the primary acquisition channel for DTC brands — must maintain substantiation files demonstrating competent and reliable scientific evidence. FTC enforcement actions in the natural health products sector have resulted in settlements exceeding USD 5 million in several precedent cases, compelling smaller brands to allocate 8–12% of marketing budgets to legal review of claims, reducing the speed-to-market advantage that should benefit innovative propolis product developers.

Policy-Created Opportunities in U.S. Propolis

The USDA's Farmers Market Promotion Program (FMPP) and Local Food Promotion Program (LFPP), both authorized under the Agricultural Marketing Act of 1946 and reauthorized through the 2018 Farm Bill, create structured demand for locally harvested propolis products through direct-to-consumer market channels. Grant awards under LFPP averaging USD 100,000–USD 500,000 enable regional beekeeping cooperatives to invest in propolis processing infrastructure, translating into higher-quality domestic supply for value-added product manufacturers. This policy creates a geographic opportunity specifically for Midwestern and Southeastern apiaries to supply premium, traceable propolis to supplement brands seeking domestic sourcing claims.

An emerging opportunity arises from the FDA's ongoing Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which subjects cosmetic products containing propolis — including lip balms, facial serums, and oral care formulations — to new mandatory safety substantiation and facility registration requirements effective December 2024. MoCRA compliance creates a barrier that disadvantages unbranded import cosmetics, effectively protecting established U.S. propolis cosmetic brands with compliant safety dossiers. Companies that complete MoCRA facility registration and product safety substantiation before enforcement intensifies in 2026 gain durable shelf space and retailer preference, representing a policy-created first-mover advantage worth capturing immediately.

Market at a Glance

Leading Market Participants

• Beekeeper's Naturals
• NOW Foods
• Comvita
• Y.S. Eco Bee Farms
• Wax Green
• Natural Health Trends Corp
• Apimaye
• Bee Health Limited
• Manuka Health New Zealand
• Zhongke-Hengyuan Biotechnology

Regulatory and Policy Environment

The primary legislation governing propolis in the United States is the Dietary Supplement Health and Education Act of 1994 (DSHEA), codified at 21 U.S.C. § 321(ff). DSHEA is administered by the FDA's Center for Food Safety and Applied Nutrition, which requires propolis supplement manufacturers to submit new dietary ingredient notifications (NDINs) when introducing ingredients not marketed before October 15, 1994. Propolis extract standardized to specific flavonoid concentrations — particularly caffeic acid phenethyl ester (CAPE) at levels above typical historical use — triggers NDIN requirements, and FDA has a 75-day review window that frequently extends in practice. The FDA has not issued a comprehensive propolis-specific guidance document, leaving manufacturers reliant on general dietary supplement enforcement precedents. Upcoming changes include the FDA's proposed rule on dietary supplement listing (DSL), anticipated in 2025–2026, which will require mandatory product listing for all supplements sold in the U.S., increasing transparency but also regulatory exposure for non-compliant propolis SKUs.

Compared to regional peers, the U.S. regulatory framework is more permissive than the European Union's, where propolis is subject to the European Food Safety Authority (EFSA) novel food authorization process under Regulation (EU) 2015/2283 and health claims are governed by Regulation (EC) 1924/2006 — both imposing higher pre-market evidentiary burdens. However, the U.S. falls behind Canada, where Health Canada's Natural Health Products Directorate issues product licenses for propolis formulations with codified efficacy standards under the Natural Health Products Regulations (SOR/2003-196), providing clearer market access pathways. The absence of a U.S. product licensing equivalent means American propolis brands operate in a compliance environment that rewards legal agility over scientific substantiation, disadvantaging long-term brand credibility development.

Long-Term Policy Outlook for U.S. Propolis

By 2032, the most consequential policy shift expected to reshape the U.S. propolis market is the potential reclassification of select propolis bioactives — particularly CAPE and galangin — as approved food additives or GRAS substances. The FDA's GRAS affirmation pathway, administered under 21 CFR Part 184, has seen renewed industry engagement following the FDA's 2023 GRAS reform discussion paper. If GRAS status is achieved for standardized propolis extract, the functional food and beverage fortification channel — currently entirely inaccessible — opens, potentially adding USD 120–150 million in incremental addressable market by 2030. This shift will primarily benefit large-scale ingredient distributors and contract manufacturers already operating food-grade facilities under 21 CFR Part 110.

The 2023 Farm Bill reauthorization, expected to be revisited in 2025 after its initial extension, is anticipated to expand apiculture support provisions under its Specialty Crops title, including increased funding for propolis yield research and domestic processing grants. If apiculture provisions mirror the expanded scope proposed in the Senate Agriculture Committee's 2023 draft, domestic propolis supply capacity is projected to increase by 20–25% by 2028, partially reducing the import dependency that currently concentrates supply risk. Simultaneously, MoCRA enforcement escalation through 2026–2028 is expected to consolidate the propolis cosmetics segment, eliminating non-compliant brands and increasing market share concentration among compliant players, which will accelerate category premiumization and elevate average selling prices across the segment.